Elevance Health (ELV) Lifted Full Year Guidance, Is The 11% Undervaluation Still There?
Elevance Health (ELV) shares are in focus after the company paired its second quarter earnings release with higher full year 2026 diluted EPS guidance of at least $20.10, despite lower quarterly net income.
See our latest analysis for Elevance Health.
The share price reaction to Elevance Health's updated guidance has come after a stronger run earlier in the year, with the 90 day share price return up 12.36% and the 1 year total shareholder return at 33.94%. The 3 year total shareholder return is down 12.97% and the 5 year total shareholder return is 10.04%, suggesting recent momentum has picked up compared with longer term performance.
If this earnings update has you reassessing healthcare exposure, it can be helpful to see what else is moving in related areas, including companies using AI in medical and health services via the 41 healthcare AI stocks.
Bulls point to Elevance Health's raised 2026 EPS floor and ongoing buybacks, while bears focus on the softer quarterly earnings. Which side does the current valuation argument appear to favor at this point?
Most Popular Narrative: 10.9% Undervalued
Against Elevance Health's last close of $389.09, the most followed narrative points to a fair value of $436.52, framing the earnings guidance upgrade within a modest valuation gap.
Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams, which should drive both topline and earnings diversity as industry healthcare spending and complexity continue to rise.
Want to see what is baked into that higher fair value for Elevance Health? Revenue mix shifts, margin rebuild assumptions and a future earnings multiple all sit at the core of this narrative.
Result: Fair Value of $436.52 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that fair value story for Elevance Health still hinges on Medicaid margins improving and medical cost trends not staying elevated in ACA and government programs.
Find out about the key risks to this Elevance Health narrative.
Next Steps
With Elevance Health's story pulling in different directions, it can help to look beyond headlines and put the numbers into your own context. To see what optimism around the stock's potential rewards looks like, start by reviewing the 4 key rewards
Looking for more investment ideas beyond Elevance Health?
If Elevance Health has you thinking more broadly about your portfolio, do not sit on the sidelines while other opportunities line up on your radar.
- Target long term compounding potential by reviewing companies flagged in the 47 high quality undervalued stocks.
- Strengthen your income stream by checking out stocks highlighted in the 7 dividend fortresses.
- Dial down portfolio shocks by focusing on companies surfaced through the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com